• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Gilead Sciences, Inc.

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Gilead Sciences to Present at Upcoming Investor Conferences
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Gilead Sciences Announces Third Quarter 2022 Financial Results
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD MGNX
    Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Gilead Sciences Completes Acquisition of MiroBio
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Gilead Sciences to Present at Upcoming Investor Conferences
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
    From Gilead Sciences, Inc.
    Via Business Wire
    Tickers GILD
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.